News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Maxigesic now licensed in 124 countries worldwide

AFT Pharmaceutical’s painkiller Maxigesic now licensed in 124 countries worldwide

AFT Pharmaceuticals (‘AFT’) has added to its existing agreements in concluding an alliance with a private European pharmaceutical company, Amicus SA Switzerland (‘Amicus’), for the licensing of the product line of its patented combination painkiller, Maxigesic, in 3 regions: the Baltics (Latvia, Estonia and Lithuania); Central Eastern Europe (Czech Republic, Hungary, Bulgaria, Romania and Slovakia); and most of the Balkans (Croatia, Slovenia, Serbia, Montenegro, Bosnia and Macedonia).

“We had previously disclosed our target to sell Maxigesic in 100 countries in our product disclosure statement,” says AFT CEO, Dr Hartley Atkinson. “This agreement, together with other recent out-licensing agreements, means that Maxigesic is now licensed in 124 countries around the world. Getting these agreements in place shows that we are expanding on our planned pathway to deliver on our sales targets.”

Currently Maxigesic is sold in eight countries. AFT has previously informed the market that it anticipates registration and product launches covering existing agreements will occur on a phased basis in these countries according to the following approximate schedule: around one-third in FY2018, around one-quarter in both FY2019 and FY2020, and the balance in FY2021.

Dr Atkinson expects that some additional launches from this current deal will take place within the closing period of the FY2018 financial year. This outcome will depend on how quickly the transfer of licenses to Amicus proceeds in some of the nations where a license has already been granted. Additional regulatory filings will also occur in Montenegro, Bosnia, Macedonia and Lithuania as soon as possible.

Maxigesic consists of a patented, fixed ratio of ibuprofen for anti-inflammation management and paracetamol (also called acetaminophen) for pain management. Maxigesic products covered by this new agreement will include tablet, sachet, oral liquid, fast-dissolve and dry powder sticks.

“We believe that these markets present good additional potential for Maxigesic as the market, defined by IMS Health for Paracetamol and Ibuprofen tablet sales for ten of the 14 countries, is in excess of US$220M,” says Dr Atkinson.

“Amicus is a good potential partner as its business teams have an excellent track record already in these complex markets. Amicus is a young, innovative and rapidly growing company with great OTC and RX market access in these specialised markets,” adds Dr Atkinson.

“This agreement with AFT marks another breakthrough for Amicus as a company,” commented Amicus Board Member and co-Founder, Petr Nemec. “The AFT relationship covers virtually all of Amicus’ existing territory as well as several new countries that we intend to enter – meaning that Maxigesic will spearhead Amicus’ entry into territories such as Hungary, Bulgaria and Czech Republic, as well as build on our strong OTC presence in existing Amicus countries.”

Amicus CEO Jean-Michel Lespinasse commented that “Amicus was honoured to be selected by AFT as its long-term licensing partner across a large central European territory. We are excited to be able to roll-out a novel pain reliever with both an efficacy and safety claim,” Lespinasse continued, pointing out that “Maxigesic marks a strategic evolution for Amicus, whereby we are licensing, long-term, a novel combination and building real value for the company. We look forward to successful launches in early 2018 and to build Maxigesic into a major brand in the territory.”

Licensing agreement with Expanscience
In May, AFT Pharmaceuticals announced an agreement with a French pharmaceutical company to out-license the product line of Maxigesic to France, Monaco, Andorra and French dependencies DOM TOMs.

At that time, French labour laws prohibited AFT from disclosing the name of the French company. In compliance with French law, AFT can now inform the market that the agreement is with the French pharma companyLaboratoires Expanscience headquartered in Courbevoie, France.

Adding to the significance of the May agreement, the new French Minister of Health, Agnès Buzyn, announced last week that opioid derivatives, including codeine, will be added to France’s list of prescription-only medicines.[1] The decision will have immediate effect. Previously, codeine-based painkillers had been available without prescription in certain strengths.

Hartley Atkinson says that the timing of the regulatory change in France is significant, particularly given that France represents the world’s second biggest market for paracetamol and ibuprofen tablet sales.

“There are three important things that have come together here,” says Dr Atkinson.

“First, Maxigesic was recommended for regulatory approval by the European Medicine Agency in May. Second, in the same month we signed a licensing agreement for Maxigesic with Expanscience which is a high-calibre local French pharma company. And third, France has just joined the growing list of countries shifting codeine-based painkillers to prescription only, meaning that this will improve the sales prospects for codeine-free Maxigesic.”
The New Zealand regulatory agency Medsafe, through its Medicines Classification Committee, is currently also considering a proposal to harmonise New Zealand regulation with Australia by up-scheduling codeine-based painkillers to prescription-only based on the risks of misuse and addition.

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis: Emerald Fennell's Promising Young Woman'


The Guardian needed not one, but three reviews to do justice to Fennell's unsettling approach, which indicates exactly how ambiguous and controversial its message really is. More>>


Howard Davis: Jill Trevelyan's Rita Angus

Although Angus has become one of Aotearoa’s best-loved painters, the story of her life remained little known and poorly understood before Jill Trevelyan's acclaimed and revelatory biography, which won the Non Fiction Award at the Montana New Zealand Book Awards in 2009, and has now been republished by Te Papa press. More>>

Howard Davis: The Back of the Painting

Painting conservators are the forensic pathologists of the art world. While they cannot bring their subjects back to life, they do provide fascinating insights into the precise circumstances of a painting's creation, its material authenticity, and constructive methodology. More>>


Howard Davis: Black Panthers on the Prowl

A passionate and gripping political drama from Shaka King, this is an informative and instructive tale of human frailty that centers around the charismatic Chicago Black Panther leader Fred Hampton, who was murdered at the age of twenty-one during a police raid. More>>

Howard Davis: Controlling the High Ground

Stephen Johnson's raw and angry film not only poses important questions with scrupulous authenticity, but also provides a timely reminder of the genocidal consequences of casual bigotry and xenophobia. More>>

Howard Davis: Dryzabone - Robert Conolly's The Dry

After the terrible devastation caused by last year’s bushfires, which prompted hundreds of Australians to shelter in the ocean to escape incineration and destroyed uncountable amounts of wildlife, The Dry has been released during a totally different kind of dry spell. More>>


Howard Davis: Hit the Road, Jack - Chloé Zhao's Nomadland

Nomadland is perhaps the ultimately 'road' movie as it follows a group of dispossessed and disenfranchised vagabonds who find a form of communal refuge in camp sites and trailer parks after the economic contraction of 2008. More>>

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland